RT info:eu-repo/semantics/article
T1 Identification, mechanism, and treatment of skin lesions in COVID-19: A review
A1 Fernández Lázaro, Diego
A1 Garrosa García, Manuel
K1 Medicina
K1 Infectious Diseases
K1 COVID-19 (Disease)
K1 SARS-CoV-2
K1 COVID-19
K1 Skin lesions
K1 Cutaneous manifestations
K1 3205 Medicina Interna
K1 3201.06 Dermatología
AB Coronavirus disease 2019 (COVID-19) is a multisystem disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), that primarily causes respiratory symptoms. However, an increasing number of cutaneous manifestations associated with this disease have been reported. The aim of this study is to analyze the scientific literature on cutaneous manifestations associated with SARS-CoV-2 by means of a narrative literature review until June 2021. The search was conducted in the following electronic databases: Medline (PubMed), SciELO, and Cochrane Library Plus. The most common cutaneous manifestations in patients with COVID-19 are vesicular eruptions, petechial/purpuric rashes, acral lesions, liveoid lesions, urticarial rash, and maculopapular-erythematous rash. These manifestations may be the first presenting symptoms of SARS-CoV-2 infection, as is the case with acral lesions, vesicular eruptions, and urticaria. In relation to severity, the presence of liveoid lesions may be associated with a more severe course of the disease. Treatment used for dermatological lesions includes therapy with anticoagulants, corticosteroids, and antihistamines. Knowledge of the dermatologic manifestations associated with SARS-CoV-2 contributes to the diagnosis of COVID-19 in patients with skin lesions associated with respiratory symptoms or in asymptomatic patients. In addition, understanding the dermatologic lesions associated with COVID-19 could be useful to establish a personalized care plan.
PB MDPI
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/59262
UL https://uvadoc.uva.es/handle/10324/59262
LA eng
NO Viruses, 2021, vol. 13, n. 10, 1916
NO Producción Científica
DS UVaDOC
RD 21-may-2024